267 related articles for article (PubMed ID: 24445867)
1. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
3. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
5. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
Hicks SW; Lai KC; Gavrilescu LC; Yi Y; Sikka S; Shah P; Kelly ME; Lee J; Lanieri L; Ponte JF; Sloss CM; Romanelli A
Neoplasia; 2017 Sep; 19(9):661-671. PubMed ID: 28753442
[TBL] [Abstract][Full Text] [Related]
6. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
7. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
8. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
9. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T; Robak P
Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
[TBL] [Abstract][Full Text] [Related]
11. DuoHexaBody-CD37
Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
Zhao X; Lapalombella R; Joshi T; Cheney C; Gowda A; Hayden-Ledbetter MS; Baum PR; Lin TS; Jarjoura D; Lehman A; Kussewitt D; Lee RJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
Blood; 2007 Oct; 110(7):2569-77. PubMed ID: 17440052
[TBL] [Abstract][Full Text] [Related]
13. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
14. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
[TBL] [Abstract][Full Text] [Related]
15. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD37 targeted immunotherapy of B-Cell malignancies.
Payandeh Z; Noori E; Khalesi B; Mard-Soltani M; Abdolalizadeh J; Khalili S
Biotechnol Lett; 2018 Dec; 40(11-12):1459-1466. PubMed ID: 30293139
[TBL] [Abstract][Full Text] [Related]
17. In the spotlight: a novel CD37 antibody-drug conjugate.
Palomba ML; Younes A
Blood; 2013 Nov; 122(20):3397-8. PubMed ID: 24235129
[TBL] [Abstract][Full Text] [Related]
18. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
Krause G; Patz M; Isaeva P; Wigger M; Baki I; Vondey V; Kerwien S; Kuckertz M; Brinker R; Claasen J; Frenzel LP; Wendtner CM; Heider KH; Hallek M
Leukemia; 2012 Mar; 26(3):546-9. PubMed ID: 21886169
[No Abstract] [Full Text] [Related]
19. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
